About bluebird bio inc. - BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
BLUE At a Glance
bluebird bio, Inc.
455 Grand Union Boulevard
Somerville, Massachusetts 02145
| Phone | 1-339-499-9300 | Revenue | 29.50M | |
| Industry | Biotechnology | Net Income | -211,913,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 720.044% | |
| Fiscal Year-end | 12 / 2024 | Employees | 375 | |
| View SEC Filings |
BLUE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.138 |
| Price to Book Ratio | 1.367 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.813 |
| Enterprise Value to Sales | 8.507 |
| Total Debt to Enterprise Value | 1.316 |
BLUE Efficiency
| Revenue/Employee | 78,658.667 |
| Income Per Employee | -565,101.333 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.05 |
BLUE Liquidity
| Current Ratio | 1.408 |
| Quick Ratio | 1.293 |
| Cash Ratio | 1.154 |
BLUE Profitability
| Gross Margin | -108.672 |
| Operating Margin | -1,143.14 |
| Pretax Margin | -718.849 |
| Net Margin | -718.422 |
| Return on Assets | -36.099 |
| Return on Equity | -108.429 |
| Return on Total Capital | -40.375 |
| Return on Invested Capital | -50.126 |
BLUE Capital Structure
| Total Debt to Total Equity | 169.801 |
| Total Debt to Total Capital | 62.936 |
| Total Debt to Total Assets | 53.351 |
| Long-Term Debt to Equity | 115.361 |
| Long-Term Debt to Total Capital | 42.758 |
Bluebird Bio Inc. in the News
Workplace automation bots gain clout amid COVID-19 pandemic
The pandemic-fueled growth in the adoption of software robots designed to ease routine office work is making one task a lot easier for chief information officers: selling the idea to their corporate bosses.